FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2008
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Keating Laurie B. 		2. Issuer Name and Ticker or Trading Symbol

MILLENNIUM PHARMACEUTICALS INC [ MLNM ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
SVP and General Counsel
(Last)          (First)          (Middle)

MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/14/2008
(Street)

CAMBRIDGE, MA 02139
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   5/14/2008     D    95075   (1) D $25.00   0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee stock option (right to buy)   $13.67   5/14/2008     D        50000      (2) 9/30/2014   Common Stock   50000   $0   0   D    
Employee stock option (right to buy)   $12.98   5/14/2008     D        50000      (2) 10/29/2014   Common Stock   50000   $0   0   D    
Employee stock option (right to buy)   $12.62   5/14/2008     D        50000      (2) 11/30/2014   Common Stock   50000   $0   0   D    
Employee stock option (right to buy)   $8.41   5/14/2008     D        6401      (2) 3/3/2015   Common Stock   6401   $0   0   D    
Employee stock option (right to buy)   $13.90   5/14/2008     D        135980      (2) 2/14/2018   Common Stock   135980   $0   0   D    

Explanation of Responses:
( 1)  Reflects shares of restricted stock that were exchanged for a cash payment of $25.00 per share in connection with the merger (the "Merger") of Mahogany Acquisition Corp. with and into Millennium Pharmaceuticals, Inc.
( 2)  This option was cancelled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price and $25.00.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Keating Laurie B.
MILLENNIUM PHARMACEUTICALS, INC.
40 LANDSDOWNE STREET
CAMBRIDGE, MA 02139

SVP and General Counsel

Signatures
Joel S. Goldberg, Attorney-In-Fact 5/15/2008
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Millennium Pharmaceuticals (MM) (NASDAQ:MLNM)
過去 株価チャート
から 10 2024 まで 11 2024 Millennium Pharmaceuticals (MM)のチャートをもっと見るにはこちらをクリック
Millennium Pharmaceuticals (MM) (NASDAQ:MLNM)
過去 株価チャート
から 11 2023 まで 11 2024 Millennium Pharmaceuticals (MM)のチャートをもっと見るにはこちらをクリック